DOSEVUE

Their core work

DOSEVUE is a Belgian SME specializing in radiation dosimetry — the science of measuring how much radiation is actually delivered to tissue during medical treatment. Their work covers two distinct sensing technologies: acoustic markers (microbubbles combined with sonography) for remotely detecting radiation doses, and optical fibre sensors for real-time dose imaging during brachytherapy, a form of internal cancer radiotherapy. In practice, they develop and validate measurement tools that allow clinicians to verify and adapt radiation delivery with far greater precision than standard clinical methods allow. Their niche sits at the boundary between medical physics, oncology instrumentation, and advanced sensing — a combination few organizations can credibly claim.

What they specialise in

How they've shifted over time

In their earliest H2020 work (AMPHORA, starting 2017), DOSEVUE focused on fundamentally experimental territory: using microbubbles as acoustic contrast agents to sense radiation doses remotely via sonography and molecular acoustics. This was blue-sky instrumentation research under the FET pillar. By 2020, their focus had moved decisively toward clinical application — ORIGIN targets optical fibre dosimetry inside the body during brachytherapy, a treatment used for cervical, prostate, and other cancers. The shift is from remote acoustic sensing in a physics lab context to in-vivo optical measurement integrated into oncology workflow.

DOSEVUE is moving from experimental sensing physics toward clinically integrated dosimetry tools, suggesting future collaboration opportunities will lie in oncology device development, adaptive radiotherapy systems, and medical device validation rather than fundamental research.

How they like to work

DOSEVUE has participated in all H2020 projects as a consortium member, never as coordinator — consistent with a specialist SME that contributes specific technical expertise rather than managing large research programs. Across just two projects they engaged 15 unique partners across 8 countries, suggesting they are brought in as focused contributors to consortia assembled around their particular sensing and dosimetry capabilities. There is no evidence of repeated partner relationships, which points to project-by-project collaboration rather than a stable long-term consortium network.

DOSEVUE has built a surprisingly broad network for a two-project SME: 15 unique partners across 8 countries, indicating they operate in internationally diverse consortia. No geographic concentration is detectable from the available data, consistent with their work in niche cross-border research fields.

What sets them apart

DOSEVUE occupies an exceptionally narrow niche: a private company with hands-on expertise in both acoustic and optical approaches to radiation dosimetry for clinical use. Very few SMEs in Europe combine experimental sensing physics (microbubble acoustics) with applied oncology instrumentation (optical fibre brachytherapy dosimetry). For a consortium building a project around precision radiotherapy, real-time dose monitoring, or advanced medical sensing, DOSEVUE brings industrial SME credibility alongside genuine research-level technical depth — a combination that is hard to replace with a university group or a large instrumentation company.

Highlights from their portfolio

• AMPHORA
  The largest-funded project (EUR 376,875) and the more scientifically ambitious of the two — funded under FET, it explored microbubbles as acoustic radiation dose markers, an unconventional approach that places DOSEVUE in frontier instrumentation research.
• ORIGIN
  Directly clinically relevant: optical fibre dose imaging for adaptive brachytherapy represents a near-market technology with clear patient impact, showing DOSEVUE's capacity to work at the research-to-clinic boundary.